Inflammation: The link between insulin resistance, obesity and diabetes

Trends in Immunology

Volumn 25, Issue 1, 2004, Pages 4-7

  Dandona, Paresh ^a   Aljada, Ahmad ^a   Bandyopadhyay, Arindam ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; FOOD INTAKE; GENE MUTATION; GENETIC RISK; GLUCOSE INTAKE; HEMOCONCENTRATION; HORMONE ACTION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INSULIN RESISTANCE; MACRONUTRIENT; MEDIATOR; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVERNUTRITION; OXIDATIVE STRESS; PREDICTION; PROMOTER REGION; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIGNAL TRANSDUCTION;

EID: 0348222671     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2003.10.013     Document Type: Short Survey

References (41)

1. Hotamisligil G.S., et al. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 259:1993;87-91.
2. Kern P.A., et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest. 95:1995;2111-2119.
3. Dandona P., et al. Tumor necrosis factor-α in sera of obese patients: fall with weight loss. J. Clin. Endocrinol. Metab. 83:1998;2907-2910.
4. Mantzoros C.S., et al. Leptin concentrations in relation to body mass index and the tumor necrosis factor-α system in humans. J. Clin. Endocrinol. Metab. 82:1997;3408-3413.
5. Yudkin J.S., et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 19:1999;972-978.
6. Mohamed-Ali V., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J. Clin. Endocrinol. Metab. 82:1997;4196-4200.
7. Lundgren C.H., et al. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation. 93:1996;106-110.
8. Ofei F., et al. Effects of an engineered human anti-TNF-α antibody (CDP571), on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 45:1996;881-885.
9. Crook M.A., et al. Elevated serum sialic acid concentration in NIDDM and its relationship to blood pressure and retinopathy. Diabetes Care. 16:1993;57-60.
10. Pickup J.C., et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 40:1997;1286-1292.
11. Schmidt M.I., et al. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. Lancet. 353:1999;1649-1652.
12. Duncan B.B., et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 52:2003;1799-1805.
13. Duncan B.B., et al. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults-the ARIC study. Atherosclerosis risk in communities. Obes. Res. 8:2000;279-286.
14. Pradhan A.D., et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J.A. M.A. 286:2001;327-334.
15. Barzilay J.I., et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the cardiovascular health study. Diabetes. 50:2001;2384-2389.
16. Han T.S., et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City diabetes study. Diabetes Care. 25:2002;2016-2021.
17. Pradhan A.D., et al. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler. Thromb. Vasc. Biol. 23:2003;650-655.
18. Hak A.E., et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler. Thromb. Vasc. Biol. 19:1999;1986-1991.
19. Lemieux I., et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler. Thromb. Vasc. Biol. 21:2001;961-967.
20. Kubaszek A., et al. Promoter polymorphisms of the TNF-α (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish diabetes prevention study. Diabetes. 52:2003;1872-1876.
21. Fernandez-Real J.M., et al. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J. Clin. Endocrinol. Metab. 88:2003;2714-2718.
22. Matarese G., et al. Balancing susceptibility to infection and autoimmunity: a role for leptin? Trends Immunol. 23:2002;182-187.
23. Miller G.E., et al. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav. Immun. 17:2003;276-285.
24. Hotamisligil G.S., et al. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-α J. Clin. Invest. 94:1994;1543-1549.
25. Aljada A., et al. Tumor necrosis factor-α inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism. 51:2002;487-491.
26. Senn J.J., et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 51:2002;3391-3399.
27. Senn J.J., et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 278:2003;13740-13746.
28. Esposito K., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 106:2002;2067-2072.
29. Mohanty P., et al. Glucose challenge stimulates reactive oxygen species (ROS), generation by leucocytes. J. Clin. Endocrinol. Metab. 85:2000;2970-2973.
30. Dandona P., et al. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J. Clin. Endocrinol. Metab. 86:2001;355-362.
31. Engstrom G., et al. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes. 52:2003;2097-2101.
32. Dandona P., et al. Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti- inflammatory effect? J. Clin. Endocrinol. Metab. 86:2001;3257-3265.
33. Aljada A., et al. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J. Clin. Endocrinol. Metab. 87:2002;1419-1422.
34. Kiecolt-Glaser J.K., et al. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc. Natl. Acad. Sci. U. S. A. 100:2003;9090-9095.
35. Padgett D.A., Glaser R. How stress influences the immune response. Trends Immunol. 24:2003;444-448.
36. Surwit R.S., et al. Stress and diabetes mellitus. Diabetes Care. 15:1992;1413-1422.
37. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
38. Ghanim H., et al. Suppression of nuclear factor-κB and stimulation of inhibitor κB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J. Clin. Endocrinol. Metab. 86:2001;1306-1312.
39. Haffner S.M., et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 106:2002;679-684.
40. Dandona P., et al. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia. 45:2002;924-930.
41. Juhan-Vague I., et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J. Thromb. Haemost. 1:2003;1575-1579.